Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : GILD crawled time : 12:00 save search
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: -7.94%
H: 8.7%
C: -4.37%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.47%
H: 0.23%
C: -3.29%
pharma business financial
If you purchased brand or generic Truvada or Atripla directly from the manufacturer, you may receive a payment from a class action settlement. Under the settlement, Gilead agreed to pay $246,750,000 into a Settlement Fund
Published: 2023-10-09 (Crawled : 12:00) - prnewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.05%
H: 0.75%
C: 0.37%
payment
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
Published: 2023-07-24 (Crawled : 12:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.02%
H: 0.45%
C: -2.71%
CABA | $13.96 -7.86% -8.52% 1.1M
|
Health Technology
|
| O: -0.22%
H: 0.45%
C: -6.47%
global commercial
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.2%
H: 0.09%
C: -1.37%
hepcludex hepatitis chmp authorization positive treatment virus
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Published: 2022-12-14 (Crawled : 12:00) - ir.voyagertherapeutics.com
VYGR | $7.55 -2.46% -2.52% 1M
|
Health Technology
|
| O: -0.16%
H: 1.76%
C: -6.41%
PGEN | $1.33 1.53% 1.5% 1.1M
|
Health Technology
|
| O: 1.82%
H: 2.98%
C: 1.79%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.85%
H: 1.47%
C: 0.45%
CDNA | $8.08 -2.42% -2.48% 670K
|
Health Technology
|
| O: 0.32%
H: 4.12%
C: 1.9%
therapeutics
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
vemlidy treatment hepatitis drug virus food infection chronic hepatitis b
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 2.33%
H: 1.82%
C: -0.91%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.04%
H: 0.57%
C: -0.92%
conference therapeutics financial results
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
MGNX | $16.08 -0.12% -0.12% 590K
|
Health Technology
|
| O: 7.67%
H: 10.82%
C: 4.49%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 1.01%
H: 0.13%
C: -0.69%
collaboration
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
Prescription Drugs Market Growing to Exhibit a Remarkable Growth of USD 1,482.35 Billion with Analysis of Key Drivers, Size, Share, Growth and Opportunities by 2029
Published: 2022-08-11 (Crawled : 12:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -12.81%
H: 8.43%
C: 5.21%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.45%
H: 0.18%
C: -1.47%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.83%
H: 0.79%
C: -0.29%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.43%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -8.67%
H: 2.89%
C: 2.14%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.18%
H: 1.46%
C: 0.05%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.63%
H: 1.52%
C: 0.09%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.5%
H: 1.88%
C: 1.32%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -10.3%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.57%
H: 1.0%
C: -0.53%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.02%
H: 0.52%
C: -1.46%
growing growth market
Appia Bio Appoints Margo Roberts, Ph.D. to its Board of Directors and Names Jason Damiano, Ph.D. as Chief Scientific Officer
Published: 2022-08-09 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.03%
H: 0.76%
C: 0.68%
AlloVir Announces $126.6 Million Registered Direct Offering
Published: 2022-07-27 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.4%
H: 1.63%
C: 0.86%
ALVR | $0.74 -2.23% -2.28% 530K
|
Health Technology
|
| O: 4.99%
H: 30.79%
C: 6.61%
offering
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
preclinical hiv symposium pre-clinical vaccine
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
CRM | News S | $271.92 -1.59% -0.27% 5.9M
|
Technology Services
|
| O: 0.69%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.37%
H: 0.59%
C: -0.21%
GOOGL | News S | $155.97 0.32% 0.32% 19M
|
Technology Services
|
| O: 0.93%
H: 0.0%
C: 0.0%
GOOG | News S | $157.49 0.39% 0.39% 14M
|
Technology Services
|
| O: 1.57%
H: 0.0%
C: 0.0%
therapeutics
Gene Therapy Market to Expand at CAGR of 19.8% During Forecast Period, Observes TMR Study
Published: 2022-04-19 (Crawled : 12:00) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.41%
H: 0.47%
C: 0.02%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
therapy market
Gilead Canada launches national educational and screening initiative to address Hepatitis C infections
Published: 2021-11-30 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
education hepatitis infections
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.16 -2.8% -2.88% 690K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
Published: 2021-11-08 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
MTNB | $0.19 -1.04% 0.0% 960K
|
Health Technology
|
| O: -2.78%
H: 2.86%
C: -3.81%
biopharma financial results results
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: 2.98%
H: 1.99%
C: -1.81%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.86%
H: 0.76%
C: -0.09%
cancer
Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways
Published: 2021-10-07 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.03%
H: 1.21%
C: 0.95%
molecular cancer conference preclinical pre-clinical
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.